Recent Finacing
Recent Raise
Recardio is a clinical-stage company developing Dutogliptin, a DPP-4 inhibitor activating SDF-1, in Phase 1/2 trials for acute myocardial infarction and chronic heart failure; HQ San Francisco, hub Klagenfurt.
Focus Areas
Total Raised
Funding round